Sandoz International GMBH has settled all patent litigation with AbbVie Inc. over its biosimilar version of the latter's Humira (adalimumab), the world's best-selling medicine. The agreement will see Sandoz paying royalties and launching Hyrimoz, its biosimilar of the TNF inhibitor, in Europe this year and in the US in September 2023. Sandoz's deal comes after three other companies have already signed similar agreements with AbbVie.
The deal gives Sandoz a non-exclusive licence to AbbVie's Humira IP from Oct. 16 in most EU countries and other...








